Adv Med Sci. 2013;58(2):274-81. doi: 10.2478/ams-2013-0021.
Aspirin is an antiplatelet drug which is commonly used in secondary prevention in ischemic heart disease and cerebrovascular events, and in newly diagnosed myocardial infarction. The aim of the present study was to examine effect of aspirin on the level of selected sphingolipid intermediates in plasma, erythrocytes and platelets.
Forty two healthy volunteers participated in the study. They were divided into two groups. In one group aspirin was given orally, daily, for one week in a dose of 75 mg (n=25). The subjects from the second group received one 300 mg dose of the drug (n=17). In both groups the blood was taken 4h after the last dose of aspirin. The following sphingolipid intermediates were quantified using high-pressure liquid chromatography: sphinganine, sphingosine, sphingosine-1-phosphate (S1P), sphinganine-1-phosphate (SA1P) and ceramide.
It was found that lower dose of aspirin increased the level of S1P and ceramide in erythrocytes (by 23 and 37%, respectively) having no effect on plasma and platelet sphingolipid levels. Higher dose of the drug reduced S1P and SA1P concentration in the plasma (by 16 and 10%, respectively).
We conclude that aspirin interferes with sphingolipid metabolism in blood and that this effect depends on a dose of the drug. Since S1P is a potent cardioprotectant, the reduction in its plasma concentration after the loading dose of aspirin could be undesired side effect of the drug.
阿司匹林是一种抗血小板药物，常用于缺血性心脏病和脑血管事件的二级预防，以及新发心肌梗死的治疗。本研究旨在探讨阿司匹林对血浆、红细胞和血小板中选定鞘脂中间产物水平的影响。
42 名健康志愿者参与了这项研究。他们被分为两组。一组志愿者每天口服阿司匹林 75mg，连续一周（n=25）。另一组志愿者单次口服 300mg 阿司匹林（n=17）。两组志愿者均在最后一次服用阿司匹林后 4 小时采血。采用高压液相色谱法测定以下鞘脂中间产物：神经酰胺、鞘氨醇、鞘氨醇-1-磷酸（S1P）、神经酰胺-1-磷酸（SA1P）。
发现小剂量阿司匹林增加了红细胞中 S1P 和神经酰胺的水平（分别增加了 23%和 37%），对血浆和血小板鞘脂水平没有影响。高剂量的阿司匹林降低了血浆中 S1P 和 SA1P 的浓度（分别降低了 16%和 10%）。
我们得出结论，阿司匹林干扰了血液中的鞘脂代谢，这种作用取决于药物的剂量。由于 S1P 是一种有效的心脏保护剂，因此在负荷剂量的阿司匹林后血浆中 S1P 浓度的降低可能是该药物的不良副作用。
